RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition.

No statistical difference (log-rank Mantel-Cox test) in tumor size could be observed between vehicle- and 3AP-treated mice for all tested 3AP concentrations including 10 mg/kg ( P = 0.90), 7.5 mg/kg ( P = 0.07), 5 mg/kg ( P = 0.59), and 2.5 mg/kg ( P = 0.18), while only slight significance was noted for the prexasertib-treated group ( P = 0.05) ( Fig. 9, F and G ).

also in 98 other papers